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Abstract
Methotrexate (MTX) is recognized as the anchor drug in the algorithm treating chronic arthri-
tis (RA, psoriatic arthritis), as well as a steroid sparing agent in other inflammatory conditions
(polymyalgia rheumatica, vasculitis, scleroderma). Its main mechanism of action has been related
to the increase in extracellular adenosine, which leads to the effects of A2A receptor in M1
macrophages that dampens TNF� and IL12 production and increases IL1Ra and TNFRp75. By act-
ing on A2B receptor onM2macrophages it enhances IL10 synthesis and inhibits NF-kB signaling.
MTX has also been shown to exert JAK inhibition of JAK2 and JAK1 when tested in Drosophila
melanogaster as amodel of kinase activity and in human cell lines (nodular sclerosis Hodgkin’s lym-
phoma and acute myeloid leukemia cell lines). These effects may explain why MTX leads to clini-
cal effects similar to anti-TNF� biologics in monotherapy, but is less effective when compared to
anti-IL6R in monotherapy, which acting upstream exerts major effects downstream on the JAK1-
STAT3pathway. TheMTXeffects on JAK1/JAK2 inhibition also allows tounderstandwhy the com-
bination of MTXwith Leflunomide, or JAK1/JAK3 inhibitor leads to better clinical outcomes than
monotherapy, while the combination with JAK1/JAK2 or JAK1 specific inhibitors does not seem
to exert additive clinical benefit.
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1 INTRODUCTION
Methotrexate (MTX) has become the anchor drug in RA and psoriatic
arthritis (PsA) since 1962, when Black et al. showed that it was clini-
cally effective in 21 patients with PsA1 and Hoffmeister in 1972 pub-
lished an abstract in which he showed that 11 of 29 patients with RA
had major clinical improvement at 10–15 mg/weekly2 and that the
decrease ofMTX dose led to 80% of disease relapse.
MTX is now the best first-line treatment in all the recommen-
dations by the Scientific Societies and has a retention rate at 2
years of more than 60% both in RA and in PsA, associated with an
Abbreviations: AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; b-DMARD, biological synthetic diseasemodified antirheumatic drugs; cs-DMARD, conventional synthetic disease
modified antirheumatic drugs; DHFR, dihydrofolate reductase; ET, essential thrombocythemia; GPI, glucose-6-phosphate isomerase; IL6R, IL6 receptor; MTX, methotrexate; PsA, psoriatic
arthritis; PV, policythemia vera; TCZ, tocilizumab; ts-DMARDs, targeted synthetic DMARDs.
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important clinical benefit.3 In clinical practice, once patients are con-
sider to be incomplete responders (MTX-IR), MTX is used in com-
bination with conventional synthetic disease modified antirheumatic
drugs (cs-DMARDs),4 biologicals (b-DMARDs),5 or targeted synthetic
DMARDs (ts-DMARDs).6,7
Once biologics are compared directly with MTX in clinical trials,
only tocilizumab (TCZ) and etanercept (to a lower degree, only for the
ACR 20) appear to be superior to MTX, whereas ts-DMARDs as JAK
inhibitors showed a higher efficacy thanMTXmonotherapy.8,9
How can we explain the similar efficacy of MTX to anti-TNF �
in monotherapy?
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1.1 Intracellular and extracellular mechanisms of
action ofMTX
Being a chemotherapy agent, MTX acts as a folate antagonist that
inhibits dihydrofolate reductase (DHFR) and ultimately purine syn-
thesis, blocking highly replicative cells in the S phase. These effects
can be bypassed and the clinical effects blocked by folinic acid sup-
plementation acting on the folate pathway downstream of DHFR and
relieving the inhibition of purine synthesis. However, at the lower
doses used in RA, folinic acid reduces the side effects associated
with MTX treatment without reverting its anti-inflammatory and
immune-suppressive actions but maintaining its clinical efficacy, prov-
ing that other mechanisms of action are responsible for its DMARD
activity. In addition, MTX blocks the 5-aminoimidazole-4-carboxamide
ribonucleotide transformylase (ATIC) that converts 5-aminoimidazole-
4-carboxamide ribonucleotide (AICAR) to formyl-AICAR (FAICAR).
AICAR leads toenhanced releaseof adeninenucleotides into theextra-
cellular space and converted to adenosine, which is thought to be the
major driver of the pharmacologic action ofMTX inRA.10,11 Adenosine
inhibits oxygen radical by neutrophils, suppresses monocyte-derived
cytokine/chemokine (among which TNF-� and IL12) production acting
on A2A, and through A2B AR increases IL10 production and promotes
M2macrophage activation.12
These pharmacobiologic effects may explain why the combination
therapy of MTX + anti-TNF� is more effective than MTX alone or
anti-TNF alone.5 Moreover, rituximab (RTX) and abatacept (CTLA4-
Ig) led to a better ACR 50 response or Boolean remission rate com-
pared to MTX alone, yet it did not reach statistical significance,13,14
whereas inRA, only TCZmonotherapy showed tobe clearly superior to
MTXmonotherapy.15
2 MTX AND CYTOKINE SYNTHESIS
The histopathological analysis of synovial tissue inflammation in RA
has shown that RA synovitis can be roughly divided into at least three
major groups, myeloid, lymphoid, and fibroid pathotypes, respectively.
If after MTX therapy the synovial inflammation still persists, the first
subset responds better to TNF-I and the second to IL6-R inhibition.16
Why does not IL6 inhibition receives any additive effect byMTX?
In Jurkat cells stimulated with TNF, MTX suppressed NF-kB
activation by inhibiting IkB� degradation and suppressing IkB� phos-
phorylation, effects all determined by adenosine.17 MTX leads to the
downregulation of TNF� and IL1� and to an increase of IL1Ra and
TNFRp75.18 It also inhibits NF-kB activity in T cells, via BH4 depletion,
and reduces activation of JNK, p53, and NF-kB activity in fibroblast-
like synoviocytes through the release of adenosine and adenosine
receptor activation, normalizing in vivo elevated NF-kB activity.19
In addition to these effects, in collagen-induced arthritis, Neurath
et al. demonstrated that intraperitoneal MTX injection, prior to the
development of arthritis, significantly suppressed IL15-induced syn-
thesis in splenic mononuclear cells of TNF, indirectly. However, no
significant effects were seen on IL6.20 In the glucose-6-phosphate
isomerase-induced (GPI) model of arthritis, MTX inhibits GPI-induced
arthritis, with a vanishing effect, showing its ability to significantly
reduce IL6 and IL6 receptor (IL6R) expression. Nevertheless this effect
was mirrored by the progressive decrease of SLC19A1 expression,
which is an important folate carrier for MTX intracellular uptake
(Fig. 1A). When SCL19A1 expression decreases, MTX does not exert
its effects anymore. Therefore, IL6 is the major driver of MTX unre-
sponsiveness in theGPImodel of arthritis.21 These effectsmay explain
the similar efficacy of MTX compared to TNF inhibitors used in
monotherapy but when added to TNF-inhibitors (TNF-I) MTX because
of the possible increase of IL1Ra and TNFRp75, can allow a further
control of inflammation. The MOA of TNF-I is out of the scope of
this review, yet it is important to consider that the biopharmacol-
ogy may have practical translation into the clinics. If after MTX ther-
apy the synovial inflammation still presents a lymphoid phenotype
where a stronger IL6 inhibition is likely needed, MTX will exert little
more effect.
MTX exerts its suppression on cytokines promoting the release
of adenosine producing its modulatory effect on inflammatory sig-
nals through A2A and A2B receptors on macrophages leading to the
suppression of proinflammatory cytokines release (i.e., TNF-�) and
promotion of anti-inflammatory molecules (i.e., IL-10) (Fig. 1B).22
Moreover, MTX was demonstrated to repress the inflammatory signal
inRAdue to its inhibitory effect on another proinflammatorymediator,
as High-mobility group box 1 (HMGB1). In particular, MTX interferes
withHMGB1 and RAGE ligand, at molecular level, acting via JAK/STAT
pathwaywith a repression of TNF-� overproduction.23,24
3 LEFLUNOMIDE, AURANOFIN, AND MTX:
JAK-STAT INHIBITION
The first cs-DMARD showing a potential intracellular effect on tran-
scription factors of the JAK/STAT pathway was Leflunomide (LFN). In
1998, Siemasko showed that in spleen cells from B10 E mice,25 LFN
diminished the tyrosine phosphorylation of JAK3 and STAT6 at con-
centrations of 100–200μM. Moreover, another cs-DMARD as Aura-
nofin, markedly inhibited IL-6-induced phosphorylation of JAK1 at
concentrations of 1.3μM and STAT3 in human Hep2 cell lines.26 Aura-
nofin inhibited constitutive and IL6-induced activation of JAK2 and
phosphorylation of STAT3 in the range of 6 mg/day in humans. The
most interesting results on csDMARDs were presented in 2015, when
Thomas reported that MTX inhibited JAK/STAT pathway activity in
Drosophila melanogaster used as a low complexity model system to
screen the action of small molecules on JAK-STAT pathways.27 When
tested in human cells lines (HDLM2—Hodgkin’s lymphoma derived,
HEL—Acute myeloid leukemia expressing JAK2 V617F variant, a gain
of function mutation associated with most human myeloprolifera-
tive neoplasms), MTX significantly reduced JAK1 phosphorylation and
STAT1 and STAT5 phosphorylation at concentrations of 0.4–0.8μM
in RA. When tested in the human Hodgkin’s lymphoma-derived cell
lines, MTX inhibited phosphorylation of STAT 1 and STAT5 but not of
STAT3. Similarly, taken orally, 1μM ruxolitinib, a JAK1/JAK2 selective
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F IGURE 1 (A, B) MTXmechanisms of action and anti-inflammatory properties of adenosine on macrophages. (A) Intracellular uptake through
SLC19A receptor, extracellular increase in Adenosine and repression ofNF-kB activity. These effects and the inhibition of JAK-1/JAK-2 repress the
autoimmune inflammation. (B) Schematic view of the anti-inflammatory activities of adenosine onM1 andM2macrophages
inhibitor produced a deeper suppression of STAT5 phosphorylation.
Interestingly, transgenic mice in which the JAK2 locus was replaced by
the human JAK2 V617F allele, developing essential thrombocythemia
(ET)- and policythemia vera (PV)-like neoplasms showed a significant
reduction of STAT3-STAT5 phosphorylation in splenocytes of homozy-
gous mice treated withMTX,28 while in silico modeling suggested that
this inhibition may be the result of a direct binding of MTX to the
JAK2 kinase domain ATP binding pocket. Accordingly, in two patients
with myeloproliferative disorders as PV and ET, MTX at 10 mg weekly
allowed the reduction of constitutional symptoms and the normaliza-
tion of hematological valueswithin 2months and their maintenance.29
Finally, molecular studies performed on RA patients and SLE patients
demonstrated that low-dose MTX reduced in vivo JAK/STAT pathway
activity,30 supporting the hypothesis thatMTXmay act via inhibition of
the JAK/STAT signaling.
4 MTX, TNF-I , AND TOCILIZUMAB IN
CLINICAL TRIALS
In all clinical trials, including TNF� inhibitors (i.e., infliximab, adali-
mumab, golimumab, certolizumab, and etanercept), the rate of ACR50
or DAS-remission achievement was not statistically different when
comparing patients treated with monoclonals alone and MTX alone.
On the other hand, the combination of b-DMARD andMTX, was asso-
ciated with a significant reduction in joint damage compared to MTX
alone and in MTX naive patients only.31 Considering mechanisms of
action other than TNF inhibition, only TCZ proved to be clearly supe-
rior toMTX.9
Therefore, we hypothesize that MTX has similar efficacy to anti-
TNF monotherapy through Adenosine and JAKs inhibition. However,
selective JAK inhibition does not directly suppress TNF synthesis by
immunecells.32 Therefore, the additive role ofMTX,whenused in com-
bination with TNF inhibitors, may be supported in vivo in RA by the
MTX suppressive effects on IL1� , IL3, IL5, IFN� , and as expected from
the JAK1 inhibition, also on IL6.33
In clinical trials, TCZ was demonstrated to be superior to MTX,
and to be more successful in RA patients who are incomplete
responders to TNF inhibition.9 In fact, IL6 signaling through IL6-
IL6R-gp130 binding, leads to JAK1/JAK2/STAT3 activation.32 There-
fore, TCZ acting upstream of JAKs and blocking the interaction
of IL6 with its receptors, can more strongly suppress the inflam-
matory signal and once MTX is added, acting downstream, lim-
ited additional effects are registered. These insights may allow to
understand why TCZ appears to be the only b-DMARD superior to
MTX alone.34
5 JAK INHIBITORS AND MTX
The inhibition of JAK-STAT phosphorylation has been tested in
Drosophila as a cell model to screen small molecules, as well as in sev-
eral immune cells, like splenocytes, T lymphocytes, and whole blood
or directly on enzyme assays.35–38 When JAK inhibitors are tested,
strong inhibition of JAK1 also inhibits JAK1/JAK3-dependent IL-15
signaling.When assessed in kinase assays using 1mMATP, none of the
compounds are only JAK3 selective and all inhibit both JAK1/JAK3-
dependent IL-15 signaling and JAK1/TYK2-dependent interferon �
signaling.39 This explains why at high concentrations compounds
inhibiting JAK1-3 may also inhibit JAK2, thus, displaying a pan-JAK
inhibition. JAK1-2-3-TYK2 inhibition and the effects on the inflam-
matory pathways have been comprehensively discussed in several
1066 GREMESE ET AL.
JAK1
IL-2
IL-4
IL-7
Receptor
sharing γ-chain
IFN-γ
Receptors
sharing gp130
Hormone
receptors
IL-3R familiy
Type1 IFNR
IL-10R family
IL-12R family
sharing p40
Type II IFNR
IL-9
IL-15
IL-21
IL-6
IL-13
G-CSF
...
IFNα
IFNβ
IL-10
...
IL-12
IL-23
GM-CSF
EPO
IL-3
IL-5
JAK1
JAK1JAK2
JAK2
JAK2 JAK2
JAK2Tyk2
JAK1
Tyk2 Tyk2JAK3
STAT1
STAT3
STAT5
STAT1
STAT3
STAT5
STAT1
STAT2
STAT5 STAT3 STAT3
STAT4
TNF-inhibitors
Tocilizumab
Baricitinib
Tofacitinib
Methotrexate ?
? ?
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reviews.39,40 JAK3 appears to be mainly involved in hematopoietic
cells and has a crucial role in lymphocyte biology while JAK1,2 and
TYK2 are expressed ubiquitously.37 For this reason, JAK3 inhibition
appeared to be a first rational target in rheumatic inflammatory dis-
eases. The randomized clinical trial comparing tofacitinib and MTX
showed a higher effectiveness of tofacitinib at 5 and 10 mg com-
pared to MTX at 10–20 mg/week,6 suggesting that specific inhibition
of JAK1/JAK3, by tofacitinib, appears tobe superior toMTX,whichacts
by inhibiting JAK1/JAK2.
When used in combination, MTX plus tofacitinib showed similar
clinical effect to MTX plus adalimumab,41 suggesting that the specific
inhibition led by tofacitinib combined with JAK1/JAK2 inhibition by
MTX may have additive effects. The same results did not occur with
baricitinib, which acts on JAK1/JAK2. In fact, clinical trial showed that
the addition ofMTX to baricitinib does not result in significantly better
clinical benefits, already obtained by baricitinib alone, which can res-
cueMTX incomplete responders owing to its specific inhibition, though
the combination led to a better control of erosions.42 Finally, given the
different JAK targets being inhibited, it can be hypothesized that the
combination of baricitinib plus LFN might be of clinical interest con-
sidering that LFN inhibits JAK3 and this may explain also the additive
effect of LFNwhen used in combination withMTX.43 The same should
occur with Upadacitinib and Filgotinib.44,45 When examining the side
effects associated to JAK inhibitors, the major one is represented
by the occurrence of Herpes Zoster infection.46 Despite discordant
results have been described in the literature,47 yet most recent data
suggest that Zoster infection may be a side effect of MTX therapy.48
All these data suggest that MTX may indeed display JAK1/JAK2
inhibition in vivo.
6 PERSPECTIVES
MTX is a fundamental part of the therapeutic strategy in several
inflammatory and autoimmune diseases. Its efficacy is recognized as
a fundamental first step approach in several inflammatory diseases.
Its effects on the purinergic pathways through adenosine modulation
and on NF-kB signal together with emerging insights into its action on
JAK1/JAK2 pathways (Fig. 2) suggest that it will certainly remain the
anchor drug of excellence in the clinics.
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